Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Direct current therapy (DCT) for malignant tumors].

Y L Xin1

  • 1China-Japan Friendship Hospital, Beijing.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|November 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Detection of Ultrahigh Energy Emission from Gamma-Ray Binary LS I +61° 303.

Physical review letters·2026
Same author

[A cohort study of association between greenbelt around schools and non-suicidal self-injury behaviors in children and adolescents].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026
Same author

Evidence of Cosmic-Ray Acceleration up to Sub-PeV Energies in the Supernova Remnant IC 443.

Physical review letters·2026
Same author

Precise Measurement of the Cosmic Ray Helium Spectrum above 0.1 PeV.

Physical review letters·2026
Same author

All-Sky Search for Individual Primordial Black Hole Bursts with LHAASO.

Physical review letters·2025
Same author

Measurement of Very-High-Energy Diffuse Gamma-Ray Emissions from the Galactic Plane with LHAASO-WCDA.

Physical review letters·2025
Same journal

[shRNA-mediated downregulation of TERT inhibits melanoma in vitro and in vivo].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026
Same journal

[Exploration on the application of perineal lateral arc-shaped incision in the resection of complex tumors on the lateral side of the pelvic floor].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026
Same journal

[Risk stratification assessment of brain metastasis in newly diagnosed non-stage IV breast cancer patients with HER-2-low expression following systemic therapy].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026
Same journal

[Clinicopathological analysis of SMARCA4-deficient tumors of digestive system origin].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026
Same journal

[cfDNA sequencing reveals response heterogeneity to first-line camrelizumab plus chemotherapy in esophageal squamous cell carcinoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026
Same journal

[Efficacy and safety of combination immunotherapy for locally advanced esophageal carcinoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026
See all related articles

Ductal Carcinoma Therapy (DCT) shows a 77.7% response rate in 216 malignant tumor patients. DCT is effective for various cancers, particularly superficial tumors, in patients ineligible for standard treatments.

Area of Science:

  • Oncology
  • Tumor Biology
  • Cancer Therapeutics

Context:

  • Malignant tumors pose significant treatment challenges, especially for patients unsuitable for conventional therapies like surgery, radiotherapy, or chemotherapy.
  • Ductal Carcinoma Therapy (DCT) presents an alternative treatment modality for a range of cancers.
  • Superficially located tumors (e.g., melanoma, skin, thyroid, breast, mouth) and deep-seated cancers (e.g., liver, adrenal gland, lung, uterine cervix) are among the candidates for DCT.

Purpose:

  • To present the treatment outcomes of 216 malignant tumor patients managed with Ductal Carcinoma Therapy (DCT).
  • To evaluate the efficacy of DCT in patients with various cancer types and locations, particularly those with contraindications to standard treatments.
  • To assess the response rates of DCT across different tumor types and stages.

Related Experiment Videos

Summary:

  • A study evaluated 216 patients with malignant tumors treated by Ductal Carcinoma Therapy (DCT).
  • The overall response rate for DCT was 77.7%.
  • DCT demonstrated effectiveness in treating both superficial and deep-seated cancers, including melanoma, skin, thyroid, breast, mouth, liver, adrenal gland, lung, and uterine cervix cancers, especially in patients unsuitable for surgery, radiotherapy, or chemotherapy. However, advanced lesions and generalized metastases showed poor response.

Impact:

  • Ductal Carcinoma Therapy (DCT) offers a viable treatment option with a high overall response rate (77.7%) for a significant number of cancer patients.
  • The findings suggest DCT's potential utility in managing various malignant tumors, expanding therapeutic possibilities for patients with limited conventional treatment options.
  • Further research may explore optimizing DCT for advanced disease stages and generalized metastases to improve outcomes for all cancer patients.